Almirall and Absci Corporation are expanding their ongoing AI Drug Discovery collaboration with Almirall’s selection of a second target aimed at dermatological indications.
The collaboration, originally announced in November 2023, combines Absci’s Integrated Drug Creation platform with Almirall’s dermatology expertise to accelerate the development of novel therapeutics for skin diseases. The expansion follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci.
Under the terms of the collaboration, Absci is leveraging its generative AI platform combined with its wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development programs of those candidates. Absci is eligible to receive up to approximately $650 million in upfront, R&D, and post-approval milestone payments across both programs, plus royalties on potential product sales.
